Share Price and Basic Stock Data
Last Updated: November 28, 2025, 11:04 am
| PEG Ratio | 0.27 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Entero Healthcare Solutions Ltd operates in the Pharmaceuticals industry and has demonstrated notable revenue growth over recent years. The company reported sales of ₹3,300 Cr for the financial year ending March 2023, up from ₹2,522 Cr in March 2022. This upward trajectory continued, with sales rising to ₹3,922 Cr in March 2024 and further projected to reach ₹5,096 Cr by March 2025. Quarterly data indicates consistent growth in sales, with ₹996 Cr recorded in September 2023, and ₹1,359 Cr anticipated by December 2024. This reflects a robust demand for its products and services, suggesting effective market positioning. The operating profit margin (OPM) has also improved, standing at 4% for the financial year ending March 2025, compared to 2% in March 2023, indicating enhanced operational efficiency. Overall, Entero’s revenue trends showcase its capacity to capture market share and respond positively to industry demands.
Profitability and Efficiency Metrics
Entero Healthcare’s profitability metrics reveal a significant improvement in its financial performance. The net profit increased substantially from a loss of ₹11 Cr in March 2023 to a profit of ₹107 Cr in March 2025, demonstrating effective cost management and operational efficiency. The company’s earnings per share (EPS) also reflect this positive trend, rising to ₹21.80 for the financial year 2025 from a negative ₹28.12 in 2023. The interest coverage ratio (ICR) of 5.07x further highlights the company’s ability to meet its interest obligations comfortably, suggesting financial stability. The return on equity (ROE) stood at 5.49%, which, while modest, indicates a return to profitability after previous losses. Additionally, the cash conversion cycle of 80 days suggests effective management of working capital, although it could be improved to align with best practices in the industry.
Balance Sheet Strength and Financial Ratios
The balance sheet of Entero Healthcare Solutions Ltd reflects a relatively stable financial position, with no reported borrowings and a total debt to equity ratio of 0.17. This low leverage indicates a conservative approach to financing, reducing financial risk. The book value per share has improved significantly to ₹396.28 in March 2025 from negative values in previous years, demonstrating a recovery in net worth. The company’s current ratio of 2.46 and quick ratio of 1.68 indicate strong liquidity, providing a buffer against short-term liabilities. However, the price-to-book value (P/BV) ratio of 2.87x suggests that the stock may be trading at a premium compared to its book value, which could raise concerns for value investors. Overall, Entero’s balance sheet shows strength but also highlights areas for potential improvement, particularly in optimizing asset utilization.
Shareholding Pattern and Investor Confidence
Entero’s shareholding pattern indicates a diversified ownership structure, with promoters holding 52.42% of the company, which provides stability and confidence in management. Foreign institutional investors (FIIs) hold 14.68%, while domestic institutional investors (DIIs) account for 9.64%, reflecting a moderate level of institutional interest. The public holds 23.26%, with a total of 36,334 shareholders as of March 2025. This distribution suggests that while there is a strong promoter presence, the company has also attracted institutional investment, which is often viewed positively by the market. However, the declining trend of FII ownership from 23.30% in March 2024 to 14.68% may signal some concerns among foreign investors regarding future growth prospects. Thus, while the internal shareholder structure appears solid, external market sentiment may require close monitoring.
Outlook, Risks, and Final Insight
Looking ahead, Entero Healthcare Solutions Ltd faces both opportunities and challenges. The company’s strong revenue growth trajectory and improving profitability metrics present a compelling case for potential investors. However, the risks include fluctuating market conditions and the need for continuous innovation in a competitive pharmaceuticals landscape. Additionally, the decline in FII interest may indicate potential concerns regarding future growth or market positioning. The company must focus on maintaining its operational efficiencies and enhancing its market share while managing costs effectively to sustain profitability. If Entero can navigate these challenges successfully, it could solidify its position as a key player in the pharmaceuticals sector, capitalizing on its recent growth trends and profitability improvements.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Entero Healthcare Solutions Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 164 Cr. | 130 | 247/84.3 | 36.2 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,467 Cr. | 410 | 479/192 | 92.5 | 24.3 | 0.16 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.5 Cr. | 46.5 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 41.0 Cr. | 28.0 | 29.3/17.0 | 97.7 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,336.40 Cr | 1,175.88 | 52.22 | 202.44 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 829 | 887 | 899 | 996 | 993 | 1,034 | 1,097 | 1,301 | 1,359 | 1,339 | 1,404 |
| Expenses | 810 | 867 | 873 | 968 | 964 | 1,005 | 1,067 | 1,258 | 1,309 | 1,290 | 1,354 |
| Operating Profit | 19 | 20 | 26 | 29 | 29 | 29 | 30 | 42 | 50 | 49 | 50 |
| OPM % | 2% | 2% | 3% | 3% | 3% | 3% | 3% | 3% | 4% | 4% | 4% |
| Other Income | 2 | 1 | 1 | 2 | 2 | 9 | 13 | 11 | 8 | 7 | 6 |
| Interest | 13 | 13 | 14 | 18 | 16 | 17 | 10 | 11 | 10 | 10 | 11 |
| Depreciation | 5 | 7 | 6 | 6 | 6 | 7 | 7 | 7 | 8 | 8 | 9 |
| Profit before tax | 2 | 1 | 7 | 7 | 8 | 14 | 27 | 35 | 39 | 37 | 36 |
| Tax % | -44% | 490% | 6% | 23% | 16% | -56% | 25% | 25% | 25% | 16% | 17% |
| Net Profit | 4 | -4 | 6 | 5 | 7 | 21 | 21 | 26 | 29 | 31 | 30 |
| EPS in Rs | 8.05 | -9.05 | 15.18 | 3.19 | 4.22 | 4.82 | 4.62 | 5.43 | 5.85 | 5.91 | 6.39 |
Last Updated: August 19, 2025, 3:47 pm
Below is a detailed analysis of the quarterly data for Entero Healthcare Solutions Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 1,404.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,339.00 Cr. (Mar 2025) to 1,404.00 Cr., marking an increase of 65.00 Cr..
- For Expenses, as of Jun 2025, the value is 1,354.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,290.00 Cr. (Mar 2025) to 1,354.00 Cr., marking an increase of 64.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 50.00 Cr.. The value appears strong and on an upward trend. It has increased from 49.00 Cr. (Mar 2025) to 50.00 Cr., marking an increase of 1.00 Cr..
- For OPM %, as of Jun 2025, the value is 4.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 4.00%.
- For Other Income, as of Jun 2025, the value is 6.00 Cr.. The value appears to be declining and may need further review. It has decreased from 7.00 Cr. (Mar 2025) to 6.00 Cr., marking a decrease of 1.00 Cr..
- For Interest, as of Jun 2025, the value is 11.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 10.00 Cr. (Mar 2025) to 11.00 Cr., marking an increase of 1.00 Cr..
- For Depreciation, as of Jun 2025, the value is 9.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 8.00 Cr. (Mar 2025) to 9.00 Cr., marking an increase of 1.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 36.00 Cr.. The value appears to be declining and may need further review. It has decreased from 37.00 Cr. (Mar 2025) to 36.00 Cr., marking a decrease of 1.00 Cr..
- For Tax %, as of Jun 2025, the value is 17.00%. The value appears to be increasing, which may not be favorable. It has increased from 16.00% (Mar 2025) to 17.00%, marking an increase of 1.00%.
- For Net Profit, as of Jun 2025, the value is 30.00 Cr.. The value appears to be declining and may need further review. It has decreased from 31.00 Cr. (Mar 2025) to 30.00 Cr., marking a decrease of 1.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 6.39. The value appears strong and on an upward trend. It has increased from 5.91 (Mar 2025) to 6.39, marking an increase of 0.48.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: November 15, 2025, 3:25 am
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 1,350 | 1,773 | 2,522 | 3,300 | 3,922 | 5,096 | 5,673 |
| Expenses | 1,326 | 1,758 | 2,498 | 3,236 | 3,810 | 4,924 | 5,462 |
| Operating Profit | 23 | 15 | 24 | 64 | 112 | 172 | 211 |
| OPM % | 2% | 1% | 1% | 2% | 3% | 3% | 4% |
| Other Income | 5 | 11 | 4 | 6 | 14 | 39 | 25 |
| Interest | 13 | 20 | 29 | 49 | 66 | 42 | 44 |
| Depreciation | 12 | 16 | 20 | 24 | 25 | 31 | 35 |
| Profit before tax | 4 | -11 | -20 | -4 | 36 | 139 | 158 |
| Tax % | 67% | 42% | 49% | 201% | -12% | 23% | |
| Net Profit | 1 | -15 | -29 | -11 | 40 | 107 | 128 |
| EPS in Rs | 93.81 | -1,550.90 | -77.71 | -28.12 | 8.99 | 21.80 | 25.41 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -1600.00% | -93.33% | 62.07% | 463.64% | 167.50% |
| Change in YoY Net Profit Growth (%) | 0.00% | 1506.67% | 155.40% | 401.57% | -296.14% |
Entero Healthcare Solutions Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 5 years from 2020-2021 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 30% |
| 3 Years: | 26% |
| TTM: | 31% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 152% |
| 3 Years: | 73% |
| TTM: | 94% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -17% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 6% |
Last Updated: September 5, 2025, 3:26 pm
No data available for the Balance Sheet data table.
Cash Flow
| Month | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
Financial Efficiency Indicators
| Month | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Debtor Days | 63 | 50 | 54 | 57 | 57 | 59 |
| Inventory Days | 57 | 54 | 49 | 41 | 43 | 52 |
| Days Payable | 32 | 22 | 22 | 25 | 24 | 31 |
| Cash Conversion Cycle | 88 | 82 | 81 | 73 | 77 | 80 |
| Working Capital Days | 57 | 54 | 41 | 32 | 48 | 65 |
| ROCE % | 1% | 1% | 5% | 7% | 9% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 21.80 | 10.81 | -3.10 | -9.22 | -5.29 |
| Diluted EPS (Rs.) | 21.76 | 10.81 | -3.10 | -9.22 | -5.29 |
| Cash EPS (Rs.) | 31.75 | 14.90 | 31.94 | -25.16 | 92.20 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 396.28 | 377.38 | -160.39 | -144.87 | -3005.20 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 396.28 | 377.38 | -160.39 | -144.87 | -3005.20 |
| Revenue From Operations / Share (Rs.) | 1171.23 | 901.80 | 8025.80 | 6550.82 | 177973.70 |
| PBDIT / Share (Rs.) | 48.51 | 29.03 | 169.07 | 75.12 | 2547.60 |
| PBIT / Share (Rs.) | 41.45 | 23.28 | 110.13 | 23.81 | 920.00 |
| PBT / Share (Rs.) | 31.89 | 8.17 | -8.97 | -51.46 | -1083.80 |
| Net Profit / Share (Rs.) | 24.69 | 9.15 | -27.00 | -76.46 | -1535.40 |
| NP After MI And SOA / Share (Rs.) | 21.79 | 8.99 | -28.11 | -77.71 | -1553.70 |
| PBDIT Margin (%) | 4.14 | 3.21 | 2.10 | 1.14 | 1.43 |
| PBIT Margin (%) | 3.53 | 2.58 | 1.37 | 0.36 | 0.51 |
| PBT Margin (%) | 2.72 | 0.90 | -0.11 | -0.78 | -0.60 |
| Net Profit Margin (%) | 2.10 | 1.01 | -0.33 | -1.16 | -0.86 |
| NP After MI And SOA Margin (%) | 1.86 | 0.99 | -0.35 | -1.18 | -0.87 |
| Return on Networth / Equity (%) | 5.49 | 2.38 | 0.00 | 0.00 | 0.00 |
| Return on Capital Employeed (%) | 9.70 | 5.80 | 6.61 | 1.38 | 1.68 |
| Return On Assets (%) | 3.50 | 1.66 | -0.88 | -2.65 | -1.86 |
| Long Term Debt / Equity (X) | 0.00 | 0.02 | -0.45 | -0.64 | 0.00 |
| Total Debt / Equity (X) | 0.17 | 0.16 | -5.45 | -4.92 | -4.46 |
| Asset Turnover Ratio (%) | 2.02 | 2.15 | 2.71 | 2.57 | 0.00 |
| Current Ratio (X) | 2.46 | 3.34 | 1.64 | 1.84 | 2.19 |
| Quick Ratio (X) | 1.68 | 2.64 | 1.09 | 1.17 | 1.35 |
| Inventory Turnover Ratio (X) | 9.43 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 5.07 | 1.92 | 1.42 | 0.99 | 1.27 |
| Interest Coverage Ratio (Post Tax) (X) | 3.58 | 1.61 | 0.77 | -0.01 | 0.23 |
| Enterprise Value (Cr.) | 5029.50 | 3669.42 | 0.00 | 0.00 | 0.00 |
| EV / Net Operating Revenue (X) | 0.98 | 0.93 | 0.00 | 0.00 | 0.00 |
| EV / EBITDA (X) | 23.83 | 29.06 | 0.00 | 0.00 | 0.00 |
| MarketCap / Net Operating Revenue (X) | 0.97 | 1.09 | 0.00 | 0.00 | 0.00 |
| Price / BV (X) | 2.87 | 2.62 | 0.00 | 0.00 | 0.00 |
| Price / Net Operating Revenue (X) | 0.97 | 1.09 | 0.00 | 0.00 | 0.00 |
| EarningsYield | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 |
After reviewing the key financial ratios for Entero Healthcare Solutions Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 21.80. This value is within the healthy range. It has increased from 10.81 (Mar 24) to 21.80, marking an increase of 10.99.
- For Diluted EPS (Rs.), as of Mar 25, the value is 21.76. This value is within the healthy range. It has increased from 10.81 (Mar 24) to 21.76, marking an increase of 10.95.
- For Cash EPS (Rs.), as of Mar 25, the value is 31.75. This value is within the healthy range. It has increased from 14.90 (Mar 24) to 31.75, marking an increase of 16.85.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 396.28. It has increased from 377.38 (Mar 24) to 396.28, marking an increase of 18.90.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 396.28. It has increased from 377.38 (Mar 24) to 396.28, marking an increase of 18.90.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 1,171.23. It has increased from 901.80 (Mar 24) to 1,171.23, marking an increase of 269.43.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 48.51. This value is within the healthy range. It has increased from 29.03 (Mar 24) to 48.51, marking an increase of 19.48.
- For PBIT / Share (Rs.), as of Mar 25, the value is 41.45. This value is within the healthy range. It has increased from 23.28 (Mar 24) to 41.45, marking an increase of 18.17.
- For PBT / Share (Rs.), as of Mar 25, the value is 31.89. This value is within the healthy range. It has increased from 8.17 (Mar 24) to 31.89, marking an increase of 23.72.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 24.69. This value is within the healthy range. It has increased from 9.15 (Mar 24) to 24.69, marking an increase of 15.54.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 21.79. This value is within the healthy range. It has increased from 8.99 (Mar 24) to 21.79, marking an increase of 12.80.
- For PBDIT Margin (%), as of Mar 25, the value is 4.14. This value is below the healthy minimum of 10. It has increased from 3.21 (Mar 24) to 4.14, marking an increase of 0.93.
- For PBIT Margin (%), as of Mar 25, the value is 3.53. This value is below the healthy minimum of 10. It has increased from 2.58 (Mar 24) to 3.53, marking an increase of 0.95.
- For PBT Margin (%), as of Mar 25, the value is 2.72. This value is below the healthy minimum of 10. It has increased from 0.90 (Mar 24) to 2.72, marking an increase of 1.82.
- For Net Profit Margin (%), as of Mar 25, the value is 2.10. This value is below the healthy minimum of 5. It has increased from 1.01 (Mar 24) to 2.10, marking an increase of 1.09.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 1.86. This value is below the healthy minimum of 8. It has increased from 0.99 (Mar 24) to 1.86, marking an increase of 0.87.
- For Return on Networth / Equity (%), as of Mar 25, the value is 5.49. This value is below the healthy minimum of 15. It has increased from 2.38 (Mar 24) to 5.49, marking an increase of 3.11.
- For Return on Capital Employeed (%), as of Mar 25, the value is 9.70. This value is below the healthy minimum of 10. It has increased from 5.80 (Mar 24) to 9.70, marking an increase of 3.90.
- For Return On Assets (%), as of Mar 25, the value is 3.50. This value is below the healthy minimum of 5. It has increased from 1.66 (Mar 24) to 3.50, marking an increase of 1.84.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. It has decreased from 0.02 (Mar 24) to 0.00, marking a decrease of 0.02.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.17. This value is within the healthy range. It has increased from 0.16 (Mar 24) to 0.17, marking an increase of 0.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 2.02. It has decreased from 2.15 (Mar 24) to 2.02, marking a decrease of 0.13.
- For Current Ratio (X), as of Mar 25, the value is 2.46. This value is within the healthy range. It has decreased from 3.34 (Mar 24) to 2.46, marking a decrease of 0.88.
- For Quick Ratio (X), as of Mar 25, the value is 1.68. This value is within the healthy range. It has decreased from 2.64 (Mar 24) to 1.68, marking a decrease of 0.96.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 9.43. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 24) to 9.43, marking an increase of 9.43.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 5.07. This value is within the healthy range. It has increased from 1.92 (Mar 24) to 5.07, marking an increase of 3.15.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 3.58. This value is within the healthy range. It has increased from 1.61 (Mar 24) to 3.58, marking an increase of 1.97.
- For Enterprise Value (Cr.), as of Mar 25, the value is 5,029.50. It has increased from 3,669.42 (Mar 24) to 5,029.50, marking an increase of 1,360.08.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.98. This value is below the healthy minimum of 1. It has increased from 0.93 (Mar 24) to 0.98, marking an increase of 0.05.
- For EV / EBITDA (X), as of Mar 25, the value is 23.83. This value exceeds the healthy maximum of 15. It has decreased from 29.06 (Mar 24) to 23.83, marking a decrease of 5.23.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.97. This value is below the healthy minimum of 1. It has decreased from 1.09 (Mar 24) to 0.97, marking a decrease of 0.12.
- For Price / BV (X), as of Mar 25, the value is 2.87. This value is within the healthy range. It has increased from 2.62 (Mar 24) to 2.87, marking an increase of 0.25.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.97. This value is below the healthy minimum of 1. It has decreased from 1.09 (Mar 24) to 0.97, marking a decrease of 0.12.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Unable to fetch valid data for stock valuation.Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Entero Healthcare Solutions Ltd:
- Net Profit Margin: 2.1%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 9.7% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 5.49% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 3.58
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.68
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 41 (Industry average Stock P/E: 52.22)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.17
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 2.1%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Plot No. I-35, Building - B, Industrial Area, Phase - I, Faridabad Haryana 121003 | info@enterohealthcare.com http://www.enterohealthcare.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Sujesh Vasudevan | Chairperson (NonExe.&Ind.Director) |
| Mr. Prabhat Agrawal | Managing Director & CEO |
| Mr. Prem Sethi | Whole Time Director & COO |
| Mr. Rajesh Shashikant Dalal | Ind. Non-Executive Director |
| Ms. Sandhya Gadkari Sharma | Ind. Non-Executive Director |
| Mr. Arun Sadhanandham | Non Exe.Non Ind.Director |
| Ms. Sumona Chakraborty | Non Exe.Non Ind.Director |
| Mr. Kevin Rohitbhai Daftary | Non Exe.Non Ind.Director |